DiaMedica Therapeutics Inc. Common Stock

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DMAC and other ETFs, options, and stocks.

About DMAC

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD).

CEO

Rick John Pauls

CEORick John Pauls

Employees

Employees19

Headquarters

Minneapolis, Minnesota

HeadquartersMinneapolis, Minnesota

Founded

2000

Founded2000

Employees

Employees19

DMAC Key Statistics

Market cap

120.35M

Market cap120.35M

Price-Earnings ratio

-5.73

Price-Earnings ratio-5.73

Dividend yield

—

Dividend yield—

Average volume

55.78K

Average volume55.78K

High today

$3.20

High today$3.20

Low today

$3.16

Low today$3.16

Open price

$3.16

Open price$3.16

Volume

6.96K

Volume6.96K

52 Week high

$4.75

52 Week high$4.75

52 Week low

$1.67

52 Week low$1.67

DiaMedica Therapeutics Inc. Common Stock

Why Robinhood?

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). Show more

DMAC Key Statistics

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD).